detection and quantitation of insulin analogues by mass ... · detection and quantitation of...
TRANSCRIPT
Detection and Quantitation of Insulin Analogues by Mass Spectrometry J.C.Yves Le Blanc, Bradley B. Schneider and Larry J. Campbell
63rd ASMS St-Louis, June 4th, 2015
Outline
• Challenge associate with Insulin analysis with MS detection
• DMS behavior for peptide and proteins
• Effect of DMS Gap Height
- CoV Magnitude
- Resolving Power
- Peak Capacity
• Separation of insulin analogues mixtures
• Conclusion
3 © 2015 AB Sciex
Human Insulin (same as Novolin GE)
Formula; C263H395N69O78S6 (51 Amino Acids) M.W.; 5808
2 linear peptide linked by 3 S-S bridge
Total of 6 BASIC and 6 ACIDIC sites (charge range from +3 to +6)
-chain
-chain F V N Q H L C G S H L V E A L Y L V C G E R G F F Y T P K T
G I V E Q C C T S I C S L Y Q L E N Y C N
MS analysis challenges for Insulin (and analogues)
4 © 2015 AB Sciex
Insulin analysis by MSMS
Tends to fragment very poorly
- many fragment ions
Many of the dominant fragments have m/z < precursor
- tends to lead higher background noise
- except for some of the analogues
MS
MSMS
5 © 2015 AB Sciex
F V N Q H L C G S H L V E A L Y L V C G E R G F F Y T P K T
G I V E Q C C T S I C S L Y Q L E N Y C N
F V N Q H L C G S H L V E A L Y L V C G E R G F F Y T D K T
G I V E Q C C T S I C S L Y Q L E N Y C N
F V K Q H L C G S H L V E A L Y L V C G E R G F F Y T P E T
G I V E Q C C T S I C S L Y Q L E N Y C N
Human Insulin
(also Novolin GE)
M.W.: 5808
Zmax: +6
NovoRapid
(Insulin Aspart)
M.W.: 5825
Zmax: +6
Apidra
(Insulin Glulisine)
M.W.: 5828
Zmax: +7
F V N Q H L C G S H L V E A L Y L V C G E R G F F Y T K P T
G I V E Q C C T S I C S L Y Q L E N Y C N
Humalog
(Insulin Lispro)
M.W.: 5808
Zmax: +6
M.W. = 3
ISOMERS
DMS Background
SV(t) CoV
Gas
flow
To
MS
0
0
K
KN
EK
N
E
Separation due to difference
between high and low field
mobility.
Alpha ()
• A function that quantifies the
differential mobility of an ion.
• Describes how mobility changes
with separation field.
Potentially a unique fingerprint for
compound identification.
0.4
0.2
0.0
-0.2
Alp
ha
120100806040200E/N (Td)
Type A
Type B
Type C
Dynamic
Cluster/decluster
Hard Sphere
Can DMS assist in separating these analogues?
DMS Coupling to Mass Spectrometer with Adjustable Residence Time
min
2 1
K
hFWHM
Schneider et al., Mass Spectrom. Rev., 2015 (May)
SCIEX TripleTOF® 5600+ and 6600 system,
equipped with SelexION™ technology
SCIEX QTRAP™ 5500 and 6500 system,
equipped with SelexION™ technology
8 © 2015 AB Sciex
NovoRapid / Apidra DMS separation to complement LC
F V N Q H L C G S H L V E A L Y L V C G E R G F F Y T D K T
G I V E Q C C T S I C S L Y Q L E N Y C N
F V K Q H L C G S H L V E A L Y L V C G E R G F F Y T P E T
G I V E Q C C T S I C S L Y Q L E N Y C N
NovoRapid
(Insulin Aspart)
M.W.: 5825
Zmax: +6
Apidra
(Insulin Glulisine)
M.W.: 5828
Zmax: +7
M.W. = 3
Need over 300,000
resolution to
separate them in
MS mode
9 © 2015 AB Sciex
Novolin
Humologues (lyspro)
Ins-Aspart
Ins-Glulisine
Ins-Aspart (+5)
Ins-Glulisine (+5)
NovoRapid / Apidra DMS separation to complement LC DMS at SV 3750V and DMR 20psi (commercial version 1x10x30mm)
10 © 2015 AB Sciex
Insulin analogue separation by DMS
• Using commercial version of the DMS, one could achieve
separation of the NovoRapid / Apidra analogue when increasing
residence time in the DMS cell (resolving gas – DMR). ‒ This approach enable detection of each analogue in single ion monitoring
mode (SIM) with selectivity comparable to isolation of precursor ion at
300,000 resolution
• Both the dominant charge state (+5 and +6) can be resolved
using this approach (~25% valley)
• However, it was not possible to separate the isomeric pair of
insulin analogues Novolin / Humalogue using this approach.
• ….so how could we improve the resolution of the DMS cell.
11 © 2015 AB Sciex
Planar DMS Design Flexibility to Increase Resolution
Q
lwh
= residence time
l = length
w = width
h = height
Q = volumetric flow rate
DMS Schematic Length and width
selected to provide a
desired residence time.
Gap height: Defines the operational characteristics of the sensor, can not be varied
without altering the performance of the device and the waveform requirements.
Used to establish alpha-curve
versus separation field
12 © 2015 AB Sciex
Planar DMS Design Flexibility to Increase Resolution
Q
lwh
= residence time
l = length
w = width
h = height
Q = volumetric flow rate
DMS Schematic Length and width
selected to provide a
desired residence time.
S = 112 Td
h = 100 m
h = 992 m
PC: 4.7
PC: 46.7
Proline, valine, histidine, methylhistamine, minoxidil, cimetidine, reserpine, ketoconazole, berberine, benzoylecgonine, buspirone, perphenazine, and glufibrinopeptide b
1.0
0.8
0.6
0.4
0.2
0.0
Rela
tive S
ignal
3020100-10-20
CoV (V)
A
h = 25 m
PC: 1.2
1.0
0.8
0.6
0.4
0.2
0.0R
ela
tive S
ignal
3020100-10-20
CoV (V)
D
h = 4 mm
PC: 188.3
13 © 2015 AB Sciex
Alpha curves of Insulin Analogues
[M+6H]6+
[M+5H]5+
14 © 2015 AB Sciex
Determining Alpha for Insulin Analogues (Novolin/Humalogue)
-0.18
-0.16
-0.14
-0.12
-0.1
-0.08
-0.06
-0.04
-0.02
0
0 50 100 150 200 250
Alp
ha
S (Td)
Novolin 5+Humalogue 5+
-0.2
-0.18
-0.16
-0.14
-0.12
-0.1
-0.08
-0.06
-0.04
-0.02
0
0 50 100 150 200 250
Alp
ha
S (Td)
Novolin 6+
Humalogue 6+
No separation observed for the +6 ions (alpha curve overlaid)
Some separation possible with the +5 form, but not necessarily at highest separation field.
176 500u cell
used to
access
higher field
values
15 © 2015 AB Sciex
Apidra and NovoRapid have different optimum separation field for each
charge state (+5 and +6) but no necessarily at maximum field strength.
176
500u cell
used to
access
higher field
values
Determining Alpha for Insulin Analogues (NovoRapid / Apidra)
208
16 © 2015 AB Sciex
Human Insulin (Novolin) and Lispro (Humalogue) Separation on Higher-Resolution DMS with LC
(monitored by SIM of +5 Charge state) ~ 10% valley (1x10x65mm cell)
Humalogue +5
Novolin +5
2D View of SIM CoV Map
H:N (1:0) H:N (1:0.1) H:N (1:1)
17 © 2015 AB Sciex
Human Insulin (Novolin) and Lispro (Humalogue) Separation on Higher-Resolution DMS with LC
(monitored by SIM of +5 Charge state) ~ 10% valley (1x10x65mm cell)
Humalogue +5
Novolin +5
3D View of SIM CoV Map
H:N (1:0) H:N (1:0.1) H:N (1:1)
18 © 2015 AB Sciex
Insulin Aspart (NovoRapid) and Insulin Glulisine (Apidra)
Separation on Higher-Resolution DMS with LC (monitored by SIM of +5 Charge state)
Near baseline separation (5%) of both analogues for both charge sate.
Apidra +5
NovoRapid +5
Conclusions
• Ways to improve DMS peak capacity. ‒ Increasing the gap height will provide a proportional increase in peak capacity for a
given separation field, at the cost of time.
‒ Increase the separation field will usually increase peak capacity, at the cost of
sensitivity.
• Improving the DMS peak capacity (not just resolution) enables separation
of precursor ions that would require in excess of 300,000 Resolution to
distinguish analogues
• Separation of isomeric forms of INSULIN (2 amino acids reversed) was
possible with an higher peak capacity DMS cell (longer cell)
• Selective detection of insulin analogues in SIM mode was possible with
LC-DMS-MS
Acknowledgements
• Stan Potyrala
• Frank Londry
• Deolinda Fernandes
• Manuel Faur
• Farshid Tayyeb
• Mikhael Kharkine
• Tibi Gera
• John Vandermey
• Mircea Manolescu
For Research Use Only, Not for Diagnostic Use.
© 2015 AB SCIEX. The trademarks mentioned herein are
the property of AB Sciex Pte. Ltd. or their respective owners.
AB SCIEX™ is being used under license. All rights reserved. Information subject
to change without notice.